Background and objectives Hepatitis C virus (HCV) infection is associated with increased mortality and morbidity in end-stage renal failure (ESRF) patients. Despite a lower incidence and risk of transmission of HCV infection with peritoneal dialysis (PD), the optimal dialysis modality for HCV-infected ESRF patients is not known. The aim of this study was to evaluate the impact of dialysis modality on the survival of HCV-infected ESRF patients.
Introduction
Chronic hepatitis C virus (HCV) infection is an important problem in end-stage renal failure (ESRF) patients receiving maintenance dialysis, with reported prevalence rates ranging between 0.7% and 76% in different countries around the world (1) (2) (3) (4) . The presence of HCV antibody has been shown to be a significant risk factor for morbidity and mortality in dialysis populations (2, (5) (6) (7) (8) , possibly due to HCV-associated hepatic cirrhosis, hepatocellular carcinoma, and cardiovascular disease (5, 6) .
The incidence and prevalence of HCV infection are significantly lower in patients receiving peritoneal dialysis (PD) compared with those receiving hemodialysis (HD) (2,9 -15) . The postulated reasons for this observation include reduced blood transfusion requirements in PD patients (3, (15) (16) (17) and the more isolated practice of dialysis at home with minimized visits to the renal unit (every 1 to 3 months for PD rather than thrice weekly for HD) (2) . Furthermore, a number of studies suggest that environmental transmission within dialysis units is a major risk factor for HCV transmission in HD patients (4, 14, 15) . PD may therefore be an attractive option for ESRF patients with HCV infection to minimize transmission to other patients, provided survival was at least comparable to that of HD.
Unfortunately, the impact of dialysis modality on the survival of HCV-infected patients with ESRF has been subject to limited investigation. A recent publication by Chou et al. (18) of 78 PD patients and 78 propensity score-matched HD patients with chronic HCV infection reported similar survival rates. However, this study was limited by small sample size, insufficient statistical power, and single-center design. The aim of the present multicenter and multicountry investigation was to evaluate the impact of dialysis modality on the survival of HCV antibodypositive patients with ESRF. tralia and New Zealand, and the results of these tests are reported to the Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry. Recipients of pre-emptive kidney transplants and those who died or were transplanted in the first 90 days of dialysis commencement were excluded. Follow-up continued until December 31, 2008. Dialysis modality was assigned according to whether patients were receiving PD or HD on day 90 after renal replacement therapy commencement. Other data collected included demographic data, cause of primary renal disease, comorbidities at the start of dialysis (coronary artery disease, peripheral vascular disease, cerebrovascular disease, chronic lung disease, diabetes, hypertension, and smoking status), body mass index, and late referral (defined as commencement of dialysis within 3 months of referral to a nephrologist). The primary outcome measure was survival.
Statistical Analyses
Results were expressed as frequencies and percentages for categorical variables, mean Ϯ SD for continuous normally distributed variables, and median and interquartile range for continuous non-normally distributed variables. Baseline analyses were carried out by dividing patients into two groups according to whether they were receiving PD or HD at day 90. Differences between the two groups were analyzed by the chi-squared test for categorical data, the unpaired t test for continuous normally distributed data, and the Mann-Whitney test for continuous non-normally distributed data. Survival curves, survival probabilities, and estimated mean survival times were generated according to the Kaplan-Meier method on an intention-totreat basis according to dialysis modality at 90 days. Differences in the survival curves between the two groups were evaluated using the log rank test. Time to death was also evaluated by multivariate Cox proportional hazards survival analysis with backward stepwise elimination to identify the most parsimonious model. The covariates initially included in the model were age, gender, racial origin, body mass index, late referral (referral to nephrologist within 3 months of commencing renal replacement therapy), smoking status (never, former, or current), chronic lung disease, coronary artery disease, cerebrovascular disease, peripheral vascular disease, diabetes mellitus, and dialysis era. Complete data were available on all covariates. Data were censored for renal transplantation, recovery of renal function, loss to follow-up, and end of study (December 31, 2008) . Proportional hazards assumptions were checked by Schoenfeld residuals and scaled Schoenfeld residuals, examined by formal hypothesis test and graphically. First-order interaction terms between the significant covariates were examined for all models. There was no evidence of an interaction between modality and dialysis era. Data were analyzed using Stata/IC 10 (College Station, TX). P-values Ͻ0.05 were considered statistically significant.
Results
A total of 424 HCV antibody-positive, ESRF patients commenced dialysis in Australia and New Zealand during the study period (January 1, 1994, to December 31, 2008) and survived for at least 90 days. On day 90 after dialysis commencement, 134 (32%) patients were receiving PD and 290 (69%) were receiving HD. The baseline characteristics of the two groups were comparable, although there was a trend toward more frequent occurrence of female gender and coronary artery disease in the PD group (Table 1) . The proportion of HCV-infected ESRF patients treated with PD at day 90 (32%) was slightly lower than that reported for the general ESRF population in Australia and New Zealand (42%) (19) . Of the 290 HD patients, 287 (99%) were receiving facility-based HD. The rates of transplantation were comparable between HD and PD (5-year cumulative rate 17% versus 14%).
One hundred ninety-nine (47%) HCV antibody-positive patients died during the study; 37 (19%) died in the first year of dialysis commencement, and 162 (81%) died after the first year. Overall, 128 (44%) died in the HD group (27 in the first year and 101 thereafter), and 71 (53%) died in the PD group (10 in the first year and 61 thereafter) (P ϭ 0.37). The main causes of death in the HD and PD groups were cardiovascular (49% versus 43%) and infectious (8% versus 23%). On Kaplan-Meier analysis, there was no significant difference in survival between the two groups (log rank statistic 0.82, P ϭ 0.37, Figure 1 ).
To deal with potential nonproportional hazards, the follow-up period was divided into survival over the first year of dialysis and after 1 year of dialysis. Using Cox regression analysis, the mortality rates in the first year of dialysis were 13.8 per 100 patient-years (95% CI 9.46 to 20.1) in the HD group and 10.7 per 100 patient years (95% CI 5.7 to 19.8) in the PD group (univariate hazard ratio [HR] PD versus HD 0.78, 95% CI 0.42 to 1.43). After the first year of dialysis, the mortality rates were 15.9 per 100 patient-years (95% CI 13.1 to 19.4) in the HD group and 20.0 per 100 patient years (95% CI 15.5 to 25.7) in the PD group (univariate HR PD versus HD 1.24, 95% CI 0.85 to 1.80). After adjusting for other baseline characteristics in a multivariate Cox proportional hazards model using backward stepwise elimination to identify the most parsimonious model, there was no significant difference in the mortality of HCV antibody-positive patients according to whether they received PD or HD on day 90 (first year of dialysis adjusted HR 0.65, 95% CI 0.34 to 1.26; subsequent years of dialysis HR 1.27, 95% CI 0.86 to 1.88) ( Table 2) . Similar results were observed using an as-treated analysis (first year of dialysis adjusted HR 0.63, 95% CI 0.36 to 1.13; subsequent years of dialysis HR 1.08, 95% CI 0.72 to 1.62).
In view of the small number of deaths in the first year (particularly in the PD group), which may have affected statistical power and the stability of estimates, further intention-to-treat analyses were performed using the 90 days dialysis modality as a time-varying covariate in linear, log, and exponential decay models, rather than using two timevarying categories (Յ or Ͼ1 year of dialysis). In these models, the hazard ratios for PD relative to HD were 1.05 (95% CI 0.71 to 1.57), 1.03 (95% CI 0.73 to 1.47), and 1.24 (95% CI 0.77 to 2.02), respectively. Moreover, the time varying term did not reach statistical significance in either the linear (P ϭ 0.68), log (P ϭ 0.49), or exponential decay models (P ϭ 0.41), indicating that the variation in hazard by dialysis modality over time was not statistically significant.
Discussion
The present study is the largest and only comprehensive multicenter investigation to date of the impact of dialysis modality on the survival of HCV antibody-positive patients with ESRF. All-cause mortality rates were comparable between HD and PD on both univariate and multivariate analysis.
Our findings are in keeping with those of a previous, small, retrospective, case-control analysis from Taiwan (18) , in which the survival of 78 PD patients with chronic HCV infection was observed to be comparable to that of 78 propensity score-matched HD patients with chronic HCV infection (univariate hazard ratio PD versus HD 1.24, 95% CI 0.78 to 1.99). These results were remarkably similar to those of the present investigation, in spite of the higher mortality rates in the former study (median survival for HCV-infected PD patients 2.2 versus 4.5 years, respectively) and the 10-fold higher HCV prevalence rates in Taiwanese compared with Australasian ESRF patient populations (2, 18) . On forward stepwise Cox regression, Chou et al. (18) found that the significant independent predictors of mortality in HCV-infected ESRF patients were positivity for hepatitis B virus surface antigen (P Ͻ 0.01), diabetes mel- litus (P ϭ 0.01), and serum albumin (P ϭ 0.03). In contrast, the major risk factors for death in our study were older age, female gender, ESRF cause, smoking, coronary artery disease, and dialysis era. Diabetes mellitus was not independently associated with mortality, and serum albumin and hepatitis B virus surface antigen status were not collected. Taken together, these results suggest that survival rates of HCV-infected patients on PD and HD are comparable and that outcome considerations should not generally impact on decisions regarding dialysis modality selection for HCV-positive ESRF patients. Although a type 2 statistical error cannot be entirely excluded, it is estimated that the present study had 80% power to detect at least a 28% reduction in mortality of HCV antibody patients treated with PD compared with HD. In light of the negative association between dialysis modality and survival of HCVinfected ESRF patients, PD may be an attractive option for such patients because it is associated with a threefold lower risk of HCV transmission to other dialysis patients compared with HD (2). Interestingly, the point estimates for mortality of HCV-infected patients were lower for PD than HD in the first year and higher thereafter. Although these results did not reach statistical significance, they do mirror the findings reported for the effect of dialysis modality on mortality in general dialysis populations (19 -22) .
The overall survival of HCV-infected patients on dialysis in this study was inferior to that of the general dialysis population in Australia and New Zealand (19) . Our group has previously shown that mortality on dialysis was predicted by either the presence of anti-HCV antibody at baseline (adjusted HR 1.29, 95% CI 1.05 to 1.58, P ϭ 0.02) or the development of anti-HCV antibodies during the course of dialysis (adjusted HR 1.27, 95% CI 1.04 to 1.55, P ϭ 0.02) (2) . Similar findings were reported in a meta-analysis of one case-control and three prospective cohort studies of 2314 maintenance dialysis patients (23) , in which the presence of anti-HCV antibody was an independent and significant risk factor for death (relative risk 1.57, 95% CI 1.33 to 1.86). Although some of this excess mortality risk can be attributed to hepatic cirrhosis and hepatocellular carcinoma (2, 23) , the most common cause of death of HCVinfected patients in our study was cardiovascular. Chou et al. (18) reported an identical finding.
The strengths of this study included its very large sample size and inclusiveness. We included all HCV antibodypositive patients receiving dialysis in Australia and New Zealand during the study period, such that a variety of centers were included with varying approaches to HCV and dialysis management. This greatly enhanced the external validity of our findings. These strengths should be balanced against the study's limitations, which included limited depth of data collection. ANZDATA does not collect important information, such as the HCV antibody assay used, laboratory results (such as hepatic transaminase levels, other liver function tests, serum albumin, coagulation profile, HCV RNA titer, liver histology), severity of comorbidities, HCV treatment (including pegylated IFN), and individual unit HCV and dialysis management protocols. Even although we adjusted for a large number of patient characteristics, the possibility of residual con- 
Conclusions
This study demonstrated that the survival of HCV-infected ESRF patients is comparable between HD and PD, such that outcome considerations should not generally impact on decisions regarding dialysis modality selection for HCV-positive ESRF patients.
